問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

CHANGHUA CHRISTIAN HOSPITAL

List

789Cases

2026-05-01 - 2031-07-20

Phase II

Not yet recruiting
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease

  • Condition/Disease

    Ulcerative Colitis Inflammatory Bowel Diseases Colitis Colitis, Ulcerative

  • Test Drug

    SPY001-001 SPY002-091 SPY003-207

Participate Sites
7Sites

Recruiting6Sites

2025-02-01 - 2027-12-31

Phase II

Completed
A randomized, blinded, placebo-controlled phase 2 trial evaluating the safety, tolerability, quantitative pharmacology, and efficacy (MAGIC) of DNTH103 in adult patients with generalized myasthenia gravis.

  • Condition/Disease

    ● Evaluate the safety and tolerability of DNTH103 in patients with generalized myasthenia gravis (gMG) up to week 13.

  • Test Drug

    DNTH103 150 mg/mL

Participate Sites
8Sites

Recruiting8Sites

2025-02-03 - 2029-12-23

Not yet recruiting
A phase 3 randomized, double-blind, placebo-controlled trial compared TPST-1120 with Atezolizumab plus Bevacizumab to placebo plus Atezolizumab plus Bevacizumab in patients with unresectable or metastatic hepatocellular carcinoma (HCC) who had not received systemic therapy.

  • Condition/Disease

    ● Overall survival (OS) is defined as the time elapsed from random assignment until death from any cause.

  • Test Drug

    TPST-1120

Participate Sites
6Sites

Recruiting6Sites

2026-08-01 - 2035-12-31

Phase III

Not yet recruiting
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    注射液劑

Participate Sites
8Sites

Not yet recruiting1Sites

2026-08-15 - 2030-12-31

Phase III

Not yet recruiting
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)

  • Condition/Disease

    Renal Insufficiency, Chronic

  • Test Drug

    膠囊劑 錠劑

Participate Sites
16Sites

Not yet recruiting16Sites

2026-09-01 - 2028-12-31

Phase II

Not yet recruiting
An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer's Disease

  • Condition/Disease

    Alzheimer Disease

  • Test Drug

    錠劑

Participate Sites
9Sites

Not yet recruiting9Sites

2017-01-22 - 2023-12-22

Phase III

Completed
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Filgotinib (GS-6034) Filgotinib (GS-6034)

Participate Sites
8Sites

Terminated4Sites

Study ended1Sites

邱正堂
Linkou Chang Gung Medical Foundation

2025-06-09 - 2029-11-26

Active
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation

  • Condition/Disease

    Pulmonary Disease, Chronic Obstructive

  • Test Drug

    預充填式注射劑

Participate Sites
8Sites

Recruiting8Sites

2025-10-15 - 2032-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

  • Condition/Disease

    Parkinson's Disease

  • Test Drug

    注射劑

Participate Sites
6Sites

Recruiting6Sites

2025-09-01 - 2033-05-31

Phase III

Active
PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non-small Cell Carcinoma

  • Test Drug

    注射劑 注射劑

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 79
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB